Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Shire : Files 8K - Other Events

share with twitter share with LinkedIn share with facebook
share via e-mail
02/17/2017 | 07:24pm CET

Shire PLC (SHPG) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on February 17, 2017.

Shire plc has issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.

The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/936402/000095010317001531/dp73113_8k.htm

Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/936402/000095010317001531/0000950103-17-001531-index.htm

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE
12/15 SHIRE : New Formulation of ONCASPAR Receives Marketing Authorization in Europe f..
12/14 SHIRE : Novel Clinical Study Collaboration Announced Designed to Improve Clinica..
12/13 SHIRE : New Formulation of ONCASPAR®▼ (pegaspargase) Receives Marketing Au..
12/13 SHIRE PLC : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Autho..
12/11 SHIRE : Chief Financial Officer update
12/08DJSHIRE : Names John Miller as Interim CFO From Jan. 1
12/08 SHIRE : Chief Financial Officer update
12/08DJSHIRE PLC SHIRE PLC : Directorate Change
12/08 SHIRE PLC : Directorate change
12/08 SHIRE : `Orphan drugs` specialist Shire to expand India presence
More news
News from SeekingAlpha
12/15 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 15, 2017
12/13 EC OKs new formulation of Shire's Oncaspar with longer shelf life
12/07 COBAS ASSET MANAGEMENT : Comments On Third Quarter 2017
12/07 YOUR DAILY PHARMA SCOOP : Gilead's Potential, Celgene CAR-T Candidate, Cellectar..
12/06 NASH drug developers in the red after Madrigal's mid-stage success with MGL-3..
Financials ($)
Sales 2017 14 936 M
EBIT 2017 5 736 M
Net income 2017 2 313 M
Debt 2017 19 275 M
Yield 2017 0,72%
P/E ratio 2017 19,52
P/E ratio 2018 12,90
EV / Sales 2017 4,30x
EV / Sales 2018 3,90x
Capitalization 44 974 M
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Technical analysis trends SHIRE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 67,8 $
Spread / Average Target 37%
EPS Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Matt Walker Head-Technical Operations
David R. Ginsburg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-21.33%44 974
JOHNSON & JOHNSON24.03%380 546
NOVARTIS13.16%222 673
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759